Stempoint Capital’s aTyr Pharma ATYR Stock Holding History

Stempoint Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200,475	Closed	-$726K	–	85
2024 Q4	$726K	Buy	+200,475	New	+$607K	0.18%	47

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stempoint Capital's ATYR Position: Q1 2025 in Review

Stempoint Capital sold out of aTyr Pharma (ATYR) in Q1 2025, closing a stake of 200,475 shares — an estimated $726K sold.

Stempoint Capital first reported a position in ATYR in Q4 2024 and held it in 1 quarter. The position peaked at $726K in Q4 2024. 87 funds tracked by Wall St. Rank hold ATYR as of Q1 2025.

Stempoint Capital reported no remaining aTyr Pharma position as of Q1 2025 after selling out during the quarter.
Stempoint Capital sold 200,475 aTyr Pharma shares in Q1 2025, an estimated $726K.
Stempoint Capital first reported a position in aTyr Pharma in Q4 2024 and held it in 1 quarter.
Stempoint Capital's aTyr Pharma position peaked at $726K in Q4 2024.
87 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.